Koi Biotherapeutics

Koi Biotherapeutics is dedicated to pioneering advancements in biotechnology research, specifically focused on enhancing the efficacy and longevity of CAR T-cell therapies. With a commitment to innovation, Koi Biotherapeutics has developed a cutting-edge CAR-Enhancer platform designed to address the critical challenge of CAR T-cell persistence. This proprietary technology selectively promotes the generation of memory CAR T-cells, significantly improving their activity and in vivo persistence.

Koi Biotherapeutics is poised to revolutionize the landscape of CAR T-cell therapy by enabling the use of lower CAR T-cell doses. Their innovative approach has the potential to eliminate the need for ex vivo expansion and lymphodepletion, offering a more streamlined and effective treatment process. This represents a major step forward in making advanced therapies more accessible and improving patient outcomes.

Koi Biotherapeutics is driven by a vision to transform cancer treatment through groundbreaking biotechnological solutions. We invite the management team at Koi Biotherapeutics to further enrich this profile with a customized showcase of their products and achievements on our platform, enhancing their visibility and impact within the industry.